FDA Approved Cosmetic & Skin

Botulinum Toxin

also known as: BoNT, Botox, onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, rimabotulinumtoxinB, Dysport, Xeomin, Jeuveau, Myobloc

The most potent biological toxin known, purified and used in precisely-controlled microdoses as the world's leading cosmetic procedure and an FDA-approved therapeutic for migraine, hyperhidrosis, spasticity, and dystonia.

A neurotoxic protein that cleaves SNARE proteins (notably SNAP-25 for serotype A) to block acetylcholine release at cholinergic nerve terminals, producing reversible muscle paralysis that lasts 3–6 months per injection.

Mechanism of action

Heavy chain binds gangliosides (GT1b) and SV2 receptors on cholinergic presynaptic terminals, enabling receptor-mediated endocytosis. The endosome acidifies, triggering translocation of the 50 kDa light chain into the cytosol. The light chain is a zinc-dependent endopeptidase that cleaves SNARE complex proteins — SNAP-25 (serotypes A, E), VAMP/synaptobrevin (B, D, F, G), or syntaxin (C). Without intact SNARE proteins, acetylcholine-loaded synaptic vesicles cannot fuse with the presynaptic membrane, blocking neurotransmitter release and causing flaccid paralysis of the target muscle until nerve-terminal sprouting restores function.

Primary uses

Cosmetic wrinkle reduction (glabellar, lateral canthal, forehead lines)
Chronic migraine prophylaxis
Cervical dystonia and blepharospasm
Upper-limb spasticity (post-stroke, cerebral palsy)
Severe axillary hyperhidrosis
Overactive bladder and neurogenic detrusor overactivity
Strabismus
Chronic sialorrhea

Typical dosing

1–400 units (product-specific) every 3–6 months (intramuscular or intradermal injection)

Units are NOT interchangeable between products. Glabellar cosmetic dose is typically 20 units onabotulinumtoxinA; cervical dystonia 150–300 units; chronic migraine 155–195 units across 31–39 injection sites.

Regulatory status

Multiple FDA approvals across several branded products. Therapeutic indications include chronic migraine, cervical dystonia, blepharospasm, strabismus, upper-limb spasticity, overactive bladder, severe axillary hyperhidrosis, and chronic sialorrhea. Cosmetic indications include glabellar lines, lateral canthal lines (crow's feet), and forehead lines. Human LD50 (inhalation) is 1–3 ng/kg, making careful unit-based dosing essential — clinical units are product-specific and NOT interchangeable across brands.

References

[review] Dressler D, Saberi FA. "Botulinum toxin: mechanisms of action." Eur Neurol, 2005;53(1):3-9.
[review] Jankovic J. "Botulinum toxin in clinical practice." J Neurol Neurosurg Psychiatry, 2004;75(7):951-957.
[review] Burstein R, Blumenfeld AM, Silberstein SD, et al. "Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review." Headache, 2020;60(7):1259-1272.

Related peptides

Hyaluronic Acid

A naturally-occurring glycosaminoglycan, injectable cross-linked forms of which are the most-used dermal fillers worldwide and are FDA-approved for osteoarthritis-related knee pain.

Argireline

A cosmetic-industry hexapeptide marketed as "topical Botox" — reduces muscle contraction signaling at the neuromuscular junction; modest but documented effects on expression-line depth.

SNAP-8

An octapeptide cosmetic ingredient extending the Argireline concept — same SNAP-25 competitive mechanism with two additional residues and claims of enhanced activity.

Quick facts

Class

A ~150 kDa two-chain protein neurotoxin produced by Clostridium botulinum, consisting of a 100 kDa heavy chain (binding and translocation) and a 50 kDa light chain (zinc-dependent protease). Seven serotypes (A–G) are known; clinical use centers on serotypes A and B.

Subcategory

neurotoxic protein (SNARE-cleaving protease)

Sequence

~1296-amino-acid precursor cleaved into 100 kDa heavy chain + 50 kDa light chain (sequences vary by serotype; the neurotoxin is a large protein rather than a short peptide)

Molecular weight

150000 Da

Half-life

clinical effect lasts 3–6 months per injection — The molecule itself is cleared relatively quickly, but SNARE cleavage produces a prolonged functional effect that only resolves as new nerve-terminal sprouting restores neurotransmission.

Evidence level

High

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.